Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease
Open Access
- 29 February 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 31 (6) , 952-960
Abstract
The autosomal dominant polycystic kidney disease (APDKD) genotype influences renal phenotype severity but its effect on polycystic liver disease (PLD) is unknown. Here we analyzed the influence of genotype on liver phenotype severity. Clinical data were retrieved from electronic records of patients who were mutation screened with the available liver imaging (n = 434). Liver volumes were measured by stereology (axial or coronal images) and adjusted to height (HtLV). Among the patients included, 221 (50.9%) had truncating PKD1 (PKD1-T), 141 (32.5%) nontruncating PKD1 (PKD1-NT) and 72 (16.6%) PKD2 mutations. Compared with PKD1-NT and PKD2, patients with PKD1-T had greater height-adjusted total kidney volumes (799 versus 610 and 549 mL/m; P < 0.001). HtLV was not different (1042, 1095 and 1058 mL/m; P = 0.64) between the three groups, but females had greater HtLVs compared with males (1114 versus 1015 mL/m; P < 0.001). Annualized median liver growth rates were 1.68, 1.5 and 1.24% for PKD1-T, PKD1-NT and PKD2 mutations, respectively (P = 0.49), and remained unaffected by the ADPKD genotype when adjusted for age, gender and baseline HtLV. Females <48 years of age had higher annualized growth rates compared with those who were older (2.65 versus 0.09%; P < 0.001). After age 48 years, 58% of females with severe PLD had regression of HtLV, while HtLV continued to increase in males. In contrast to the renal phenotype, the ADPKD genotype was not associated with the severity or growth rate of PLD in ADKPD patients. This finding, along with gender influence, indicates that modifiers beyond the disease gene significantly influence the liver phenotype.Keywords
Funding Information
- The National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health (DK090728)
- the Mayo Translational PKD Center (DK058816-15)
- the Mayo Clinic's Center for Clinical and Translational Science
- National Institute of Health (UL1TR000135)
This publication has 30 references indexed in Scilit:
- Type of PKD1 Mutation Influences Renal Outcome in ADPKDJournal of the American Society of Nephrology, 2013
- Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severityJournal of Clinical Investigation, 2012
- Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 casesLiver International, 2010
- Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver DiseaseJournal of the American Society of Nephrology, 2010
- Reducing Polycystic Liver Volume in ADPKDClinical Journal of the American Society of Nephrology, 2010
- Progesterone stimulates the proliferation of female and male cholangiocytes via autocrine/paracrine mechanismsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- Defining a Link with Autosomal-Dominant Polycystic Kidney Disease in Mice with Congenitally Low Expression of Pkd1The American Journal of Pathology, 2006
- Lowering of Pkd1 expression is sufficient to cause polycystic kidney diseaseHuman Molecular Genetics, 2004
- Polycystic disease of the liverHepatology, 2004
- Hepatic Cysts in Autosomal Dominant Polycystic Kidney DiseaseMayo Clinic Proceedings, 1990